Table 3.

Hazard ratios and 95% confidence intervals of end-stage renal disease by quartiles of total cholesterol variability

		Events (n)	Follow-up duration (person-years)	Incidence rate (per 1000 person-years)	Model 1	Model 2	Model 3	Model 4
CV
	Q1	1649	12552854	0.13	1 (ref)	1 (ref)	1 (ref)	1 (ref)
	Q2	1859	12669787	0.15	1.15 (1.08–1.23)	1.12 (1.05–1.20)	1.11 (1.04–1.19)	1.09 (1.02–1.16)
	Q3	2338	12638900	0.19	1.39 (1.31–1.48)	1.29 (1.21–1.38)	1.25 (1.17–1.33)	1.22 (1.15–1.30)
	Q4	5401	12480864	0.43	2.66 (2.52–2.82)	2.00 (1.90–2.12)	1.73 (1.63–1.83)	1.60 (1.51–1.70)
	P for trend				< 0.0001	< 0.0001	< 0.0001	< 0.0001
SD
	Q1	1675	12546345	0.13	1 (ref)	1 (ref)	1 (ref)	1 (ref)
	Q2	1838	12692068	0.15	1.09 (1.02–1.16)	1.07 (1.00–1.14)	1.06 (0.99–1.13)	1.05 (0.98–1.12)
	Q3	2339	12600566	0.19	1.31 (1.23–1.40)	1.22 (1.15–1.30)	1.19 (1.12–1.27)	1.18 (1.11–1.26)
	Q4	5395	12503426	0.43	2.50 (2.37–2.64)	1.92 (1.81–2.03)	1.66 (1.57–1.76)	1.55 (1.46–1.65)
	P for trend				< 0.0001	< 0.0001	< 0.0001	< 0.0001
VIM
	Q1	1657	12552700	0.13	1 (ref)	1 (ref)	1 (ref)	1 (ref)
	Q2	1857	12669222	0.15	1.15 (1.07–1.23)	1.12 (1.05–1.20)	1.11 (1.04–1.18)	1.08 (1.01–1.16)
	Q3	2333	12639539	0.19	1.39 (1.30–1.48)	1.29 (1.21–1.37)	1.24 (1.17–1.33)	1.21 (1.14–1.29)
	Q4	5400	12480944	0.43	2.66 (2.52–2.82)	2.00 (1.89–2.12)	1.73 (1.64–1.83)	1.60 (1.51–1.70)
	P for trend				< 0.0001	< 0.0001	< 0.0001	< 0.0001

Model 1: adjusted for age, sex, body mass index, alcohol drinking, smoking, regular exercise and income

Model 2: adjusted for model 1 plus diabetes mellitus and hypertension

Model 3: adjusted for model 2 plus mean total cholesterol level and use of lipid-lowering agent

Model 4: adjusted for model 3 plus estimated glomerular filtration rate and proteinuria